Search
Search Results
-
Association between serum lipoprotein(a) and mildly reduced eGFR: a cross-sectional study
Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and aortic stenosis. However, the data on the relationship between Lp(a) and...
-
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
BackgroundFibroblast growth factor-23 (FGF23) has been associated to left ventricular (LV) hypertrophy and heart failure (HF) severity. We aimed to...
-
Phenogrou** heart failure with preserved or mildly reduced ejection fraction using electronic health record data
BackgroundHeart failure (HF) with preserved or mildly reduced ejection fraction includes a heterogenous group of patients. Reclassification into...
-
Timing of prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients hospitalized for acute heart failure with reduced/mildly reduced ejection fraction: a retrospective analysis
Although angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) play critical roles in the treatment of heart...
-
Effect of severity and etiology of chronic kidney disease in patients with heart failure with mildly reduced ejection fraction
ObjectiveThe study investigates the prognostic impact of the severity and etiology of chronic kidney disease (CKD) in patients with heart failure...
-
Prognostic impact of prior LVEF in patients with heart failure with mildly reduced ejection fraction
AimsAs there is limited evidence regarding the prognostic impact of prior left ventricular ejection fraction (LVEF) in patients with heart failure...
-
Predictors of mortality in heart failure patients with reduced or mildly reduced Ejection Fraction: The CASABLANCA HF Study
BackgroundHeart failure (HF) poses a significant public health challenge throughout the world and Morocco. Our objective was to delineate the...
-
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
This review provides a comprehensive overview of heart failure with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF), including its...
-
Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle
Right ventricular (RV) function is a major determinant of prognosis and adverse outcomes in patients with heart failure (HF). It is largely unknown...
-
Heart failure with mid-range or mildly reduced ejection fraction
Left ventricular ejection fraction (EF) remains the major parameter for diagnosis, phenoty**, prognosis and treatment decisions in heart failure....
-
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews
The recently published randomized trials (RCTs) evaluating the effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in heart failure with...
-
Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis
AimsTo elucidate the association between baseline renal characteristics and the disparities in renal outcomes among patients with SGLT2i treatment.
...
-
Acute heart failure with mildly reduced ejection fraction and myocardial infarction: a multi-institutional cohort study
BackgroundLittle research has been done on ischemic outcomes related to left ventricular ejection fraction (EF) in acute decompensated heart failure...
-
Minimal risk of contrast-induced kidney injury in a randomly selected cohort with mildly reduced GFR
ObjectivesPrevious large studies of contrast-induced or post-contrast acute kidney injury (CI-AKI/PC-AKI) have been observational, and mostly...
-
The clinical utility of cystatin C based eGFR in assessing renal function among HIV/AIDs patients on ART at Mildmay Uganda
BackgroundIn clinical practice, Measurement of estimated glomerular filtration rates (eGFR) is the gold standard assessing renal function the...
-
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell...
-
Long noncoding RNA XIST promotes cell proliferation and migration in diabetic foot ulcers through the miR-126-3p/EGFR axis
BackgroundThe prevalence of diabetic foot ulcers (DFUs) has caused serious harm to human health. To date, a highly effective treatment is lacking....
-
Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction
Purpose of ReviewThis review summarizes current HER2-targeted therapies and clinical studies that have investigated primary and secondary prevention...
-
-
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials
BackgroundWe assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes...
